Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Plavix litigation settlement agreement amended.
- Sanofi- Aventis (Paris, France) and Bristol- Myers Squibb (New York, NY) and Apotex, Inc. and Apotex Corporation (Toronto, Canada) announced that in response to concerns raised by the Federal Trade Commission ("FTC") and state attorneys general to the previously announced proposed settlement the companies reached with...
- Research articles 2006-06-01
- CHEMICALS : DEGUSSA GETS METHIONINE CARTEL FINE REDUCED.
- The European Union's Court of First Instance decided on 5 April to reduce the fine imposed by the European Commission in 2002 on Degussa for an illegal agreement by 27 million, cutting the overall penalty from 118.1 to 91.1 million (case T-279/02). The Court...
- Research articles 2006-04-13
- Sanofi-Aventis is optimistic after strong third quarter
- PARIS AFP — French healthcare group Sanofi-Aventis announced that net profit in the third quarter of the year had risen sharply and that the company was on track to meet its target of a 20-percent rise in earnings per share this year. The company said that adjusted net profit...
- Research articles 2005-11-08
- Pharma MNCs gear up for product patents, recast their portfolios.
- Byline: Writankar Mukherjee Apr. 13--KOLKATA, India -- The multinational pharma majors operating in India have set the ball rolling to improve their bottomlines in the product patent era. Many companies have initiated restructuring exercises to strengthen their presence in key therapeutic...
- Research articles 2005-04-13
- Sanofi-Aventis posts 18 pct profit rise in 2004, sees in-line 2005
- PARIS AFP — Sanofi-Aventis, the French pharmaceutical firm, posted forecast-beating net profit for 2004 and said it expected earnings this year to be in line with the 2004 performance. Sanofi-Aventis, formed last year in the merger of French firm Sanofi Synthelabo and Franco-German life sciences giant Aventis, said it...
- Research articles 2005-03-01
- Sanofi-Aventis receives allowance on reissuance application for Lovenox '618 patent.(Brief Article)
- Sanofi-Aventis (Paris, France) announced that a Notice of Allowance from the United States Patent and Trademark Office had been received on its subsidiary Aventis' application for reissuance of United States Patent 5,389,618 ('618 patent), relating to Lovenox. A Notice of Allowance constitutes a decision from...
- Research articles 2004-12-01
- Aventis to make flu vaccine year-round
- Aventis Pasteur, the world's largest flu vaccine manufacturer and the sole supplier of flu shots to the USA this year, will begin preparing for year-round production under a $10 million contract announced Tuesday with the U.S. Department of Health and Human Services. The contract is aimed at providing a...
- Research articles 2004-11-10
- Big Ticket Deals: Some go cold, some heat up
- New Jersey held its head high when pharmaceutical giant Sanofi-Aventis of France last month picked the state for its U.S. headquarters. But it might be too early to cheer. Sanofi-Aventis has said that it will locate those offices at Bridgewater Crossing in Bridgewater, where Aventis has its U.S. headquarters and...
- Research articles 2004-11-01
- Pharmaceutical Market Movers: +10.71%, +10.31%: NCDP, PFE, AVE, CYH, BMRN.
- M2 PRESSWIRE-23 September 2004-InvestSource Inc.: Pharmaceutical Market Movers: +10.71, +10.31: NCDP, PFE, AVE, CYH, BMRNC1994-2004 M2 COMMUNICATIONS LTD RDATE:09232004 Stocks in the News: Nicodrops Incorporated (OTC: NCDP), Pfizer Incorporated (NYSE: PFE), Aventis SA (NYSE: AVE), Community Health Systems Incorporated (NYSE:...
- Research articles 2004-09-23
- US authorities clear Sanofi takeover offer for Aventis
- WASHINGTON AFP ? US regulatory authorities conditionally agreed to accept the pending merger of French-German pharmaceutical group Aventis and its smaller French rival Sanofi-Synthelabo into the world's third-largest pharmaceutical group. The Federal Trade Commission agreed to the merger on the condition that the two companies give up key drug...
- Research articles 2004-07-29
- Aventis results hit by cost of fighting Sanofi bid
- PARIS AFP ? French-German pharmaceutical company Aventis reported a 0.3-percent fall in second-quarter net profit, blaming in part the cost of fighting a successful hostile bid by French rival Sanofi-Synthelabo. Aventis said that net profit amounted to 610 million euros (738.1 million dollars) from 612 million euros in the...
- Research articles 2004-07-28
- Sanofi says US FTC wants more information on Aventis takeover
- PARIS AFP ? French pharmaceutical group Sanofi-Synthelabo said the US Federal Trade Commission had asked for more information on Sanofi's takeover bid for French-German rival Aventis, to complete an FTC investigation. The FTC's decision would not delay the completion of the offer, expected before the end of the second...
- Research articles 2004-05-05
- WORLD MARKETS: Europe
- THE CAR maker DaimlerChrysler dragged European shares down, but defensive health stocks such as Aventis supported. The world's biggest cosmetics group L'Oreal fared well, ending up 2.2 per cent on expectations of strong Q1 sales. Germany's DAX fell 0.5 per cent; France's CAC 40 declined 0.3 per cent.
- Research articles 2004-04-08
- InvestSource Coverage Alerts: AMJL, IDCC, AVE AMRI, SNTK.
- M2 PRESSWIRE-10 March 2004-InvestSource Inc.: InvestSource Coverage Alerts: AMJL, IDCC, AVE AMRI, SNTKC1994-2004 M2 COMMUNICATIONS LTD RDATE:03102004 Amigula Incorporated (OTC: AMJL), InterDigital Communications Corporation (Nasdaq: IDCC), Aventis SA (NYSE: AVE), Albany Molecular Research Incorporated (Nasdaq: AMRI), and Senetek PLC (Nasdaq: SNTK)....
- Research articles 2004-03-10
- Targacept
- Targacept, Winston-Salem, North Carolina, a central nervous system-focused biopharmaceuticals company, has announced the addition of Errol De Souza to its board of directors. De Souza is currently president and CEO of Archemix, a biopharmaceutical company developing aptamer therapeutics, Before joining Archemix, De Souza was president and CEO of Synaptic Pharmaceutical....
- Research articles 2004-02-16
- Aventis posts 17.5 rise in 2003 net profit
- PARIS AFP ? The Franco-German pharmaceutical group Aventis posted a 17.5 percent rise in net profit for 2003 and forecast sales growth of six-seven percent this year as it fends off a takeover bid. Net profit came to 2.44 billion euros (3.07 billion dollars), on sales of 16.79 billion...
- Research articles 2004-02-05
- WORLD MARKETS: London
- BLUE CHIPS clung to scant gains as a dip for the drug giant GlaxoSmithKline and weakness in the heavily weighted financial sector forced the market off its peak. But Scottish & Newcastle frothed up 6.3 per cent amid bid rumours and optimism over its Russian partner Baltika. The FTSE 100...
- Research articles 2004-01-28
- Sanofi board discussing details of Aventis bid: source
- PARIS AFP ? The board of French pharmaceutical group Sanofi-Synthelabo was finalising a hostile bid for Franco-German rival Aventis which it was expected to launch on Monday, an informed source told AFP. "The board members are discussing the details of the offer," the source said. The takeover bid...
- Research articles 2004-01-25
- Sanofi-Synthelabo to make 50-billion-euro hostile bid for Aventis: source
- PARIS AFP ? French pharmaceutical group Sanofi-Synthelabo was set to launch a hostile 50-billion-euro (63-billion-dollar) bid for its Franco-German rival Aventis, a move which would create the third-largest company in the sector, an informed source told AFP. The massive offer, one of the biggest in French corporate history, was...
- Research articles 2004-01-26
- Hostile bid for Aventis has German unions, drug sector in a whirl
- FRANKFURT AFP ? Sanofi-Synthelabo's hostile takeover bid for its Franco-German rival Aventis has employees here fearing for their jobs and has sounded a warning to German pharmaceutical companies too small to compete. "I fear a catastrophe in Germany," said the head of Aventis Germany's work's committee, Friedhelm Conradi, after...
- Research articles 2004-01-27
- << Previous
- page 1 of 26
- Next >>
Content Types
Refining Tags
- Bayer AG (31 results)
- Pharmaceutical Company (30 results)
- SALES (28 results)
- Biotechnology (25 results)
- merger (23 results)
- food (21 results)
- corn (20 results)
- Manufacturing (19 results)
- FINANCE (19 results)
- U.S. Environmental Protection Agency (18 results)
- General Motors Corp. (18 results)
- Government (14 results)
- Novartis AG (13 results)
- Investment (13 results)
- agreement (13 results)
- acquisition (12 results)
- FTC (11 results)
- company (10 results)
- SOFTWARE (9 results)
- HEALTHCARE (9 results)
- board (8 results)
- Pfizer Inc. (8 results)
- Rhodia (8 results)
- patient (8 results)
- vaccine (7 results)
- European Commission (7 results)
- Benefits (7 results)
- FDA (7 results)
- Agence France-Presse (7 results)
- E.I. Du Pont de Nemours & Co. (7 results)
- protein (6 results)
- U.S. Department of Agriculture (6 results)
- team (5 results)
- life science (5 results)
- commission (5 results)
- Hackensack (5 results)
- Litigation (5 results)
- Sanofi-Aventis (5 results)
- Internet (5 results)
- Biovail Corp. (5 results)
- shareholder (5 results)
- marketing (5 results)
- collaboration (5 results)
- physician (5 results)
- BASF AG (4 results)
- J.P. Morgan Chase & Co. (4 results)
- Worker (4 results)
- patent (4 results)
- Goldman Sachs Group Inc. (4 results)
- U.S. (4 results)
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
